The Arthritis Translational Registry and Biorepository is a collaborative research effort of investigators in the Division, including major initiatives in rheumatoid arthritis led by Dr Greenberg, osteoarthritis led by Drs. Steven Abramson and Mukundan Attur and psoriatic arthritis led by Dr. Soumya Reddy.
The development of targeted biologic agents for the treatment of rheumatic diseases has provided an unprecedented array of highly efficacious therapeutic agents. However, not all patients with inflammatory arthritis conditions respond to these therapies. Moreover, adverse events including serious infections appear to be increased with certain biologic agents.
Dr. Greenberg and his laboratory are working on the identification of genetic and other biomarkers that can predict whether or not an individual patient will respond or experience a serious adverse event. Specifically, the teamís research is currently focused on identifying prognostic genetic biomarkers for rheumatoid arthritis patients treated with TNF antagonists and other biologic agents. Other ongoing projects include research collaborations with multiple industry partners to identify leukocyte gene expression profiles of arthritic disease susceptibility, response to biologic agents and disease progression.
Dr. Greenberg has collaborated with investigators from the Consortium of Rheumatology Researchers of North America (CORRONA) on research projects investigating the effectiveness and safety of TNF antagonists for the treatment of rheumatoid arthritis. In conjunction with Dr. Harry Ostrer from the NYU Human Genetics Program and Dr. Joel Kremer from Albany Medical College, the CORRONA-NYU Pharmacogenomics Biorepository has been established at NYU School of Medicine, collecting DNA and other biospecimens from participating sites and patients enrolled in the CORRONA rheumatoid arthritis registry.